|drug3015||standardized Lung Ultrasound (LUS) examination Wiki||0.41|
|drug1275||Ivermectin 3Mg Tab Wiki||0.41|
|drug2010||RT PCR SARS-CoV-2 Wiki||0.41|
|drug2761||biological samples, questionnaires and interviews Wiki||0.41|
|drug158||An auto-questionnaire comprising three psychometric scales Wiki||0.41|
|drug2508||This is an online survey with no intervention. Wiki||0.41|
|drug2014||RT-PCR and antibody testing Wiki||0.41|
|drug1115||Hydroxychloroquine Sulfate Tablets Wiki||0.29|
|drug2662||Vitamin C Wiki||0.12|
|D011251||Pregnancy Complications, Infectious NIH||0.41|
|D011254||Pregnancy in Diabetics NIH||0.41|
|D011024||Pneumonia, Viral NIH||0.05|
|D003141||Communicable Diseases NIH||0.04|
|D045169||Severe Acute Respiratory Syndrome NIH||0.02|
|D018352||Coronavirus Infections NIH||0.02|
There are 6 clinical trials
Currently there is a great need for an accurately and rapid assessment of patients suspected for Covid-19. Like CT, Lung Ultrasound (LUS) examination can potentially help with the initial triage of patients but also help track the evolution of the disease. LUS can be used in every setting, including settings with limited infrastructure, allowing the reduction of disparities in trials participation. LUS is also a practical approach that can be used by obstetricians/gynecologists, who are the primary care givers in the labour and delivery room. The International Lung UltraSound Analysis (ILUSA) Study is an international multicenter prospective explorative observational study to assess the predictive value of LUS in Covid-19 suspected and diagnosed pregnant patients.
Description: The primary endpoint is diagnostic performance in terms of the area under the receiver operating characteristic curve (AUC, also known as the c-statistic) and sensitivity and specificity with regard to the prediction of poor outcome. Outcome at one week from admission: good outcome includes discharge or inpatient breathing in free air; poor outcome includes patient with oxygen support, patients with CPAP/ high oxygen flow cannula, or patient with endotracheal intubation during the week.Measure: Diagnostic performance of LUS to predict poor outcome Time: outcome one week after enrollment into the study
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
Description: Post-traumatic Stress Disorder (PTSD) Symptoms will be assessed by the Impact of Events Scale-6. This scale includes a total of six items: two items from each of the three subscales of the measure, namely intrusion, hyperarousal and avoidance. Participants will be asked to report their PTSD symptoms in the past 7 days on a Likert Scale ranging from 0 (not at all) to 4 (extremely).Measure: Post-traumatic Stress Disorder Time: Anytime during pregnancy or within 6 months after given birth.
Description: Symptoms of anxiety and depression will be measured by the Patient Health Questionnaire-4 (PHQ-4) which combines two ultrabrief screeners: the PHQ-2 and the Generalised Anxiety Disorder Scale. Participants will be asked to report their symptoms of depression and anxiety in the past 2 weeks on a Likert Scale from 0 (not at all) to 3 (nearly every day) for a maximum score of 12.Measure: Anxiety and Depression Time: Anytime during pregnancy or within 6 months after given birth.
This is a multicenter prospective study that aims to investigate the clinical impact of SARS-CoV-2 infection in pregnant women, pregnancy outcomes and perinatal transmission.
Description: Positive Sars-Cov-2 RT PCR in nasopharyngeal/oral swab tests or presence of IgM in blood samplesMeasure: SARS-CoV-2 Neonatal Infection Time: 7 days
Description: stillbirths and deaths in the first week of lifeMeasure: Perinatal mortality Time: 35 weeks
Description: maternal ICU admission due to COVID-19Measure: ICU maternal admission Time: 35 weeks
Description: Newborn 5 minute Apgar Score < 7Measure: 5 minute Apgar Score < 7 Time: 1 day
Description: Delivery between 24 and 36 weeksMeasure: Preterm labour Time: 35 weeks
Description: Preterm premature rupture of the membranes between 24 and 36 weeksMeasure: PPROM Time: 35 weeks
Description: spontaneous pregnancy loss before 24 weeksMeasure: Miscarriage Time: 14 weeks
The aim of this study is to capture data, laboratory markers, and clinical outcomes of obstetric and neonatal outcomes in cases of COVID-19 during pregnancy in Cuyahoga County.
Description: Viral presence in any of the collected specimensMeasure: Presence of COVID-19 virus Time: At time of delivery
Description: Antibodies detected in any of the collected specimensMeasure: Presence of antibodies to COVID-19 virus Time: At time of delivery and 24 hours of life of the newborn
Description: Innate/Adaptive cell function and immune responseMeasure: Immune responses to COVID-19 virus What is the Immune responses of a mother infected with COVID-19 and neonates? What is the Immune responses of a mother infected with COVID-19 and neonates? Immune response to COVID-19 virus Time: At time of delivery and 24 hours of life of the newborn
Purpose: The emergence of a new coronavirus, coronavirus 2 (SARS-CoV-2) causing a novel infection in the human race resulting in a world-spanning pandemic came as a surprise and at a tremendous cost both for individual human lives as well as for the society and for the health care sector. The knowledge on how this new infection affects both the mother and the unborn child as well as the outcomes for the mother and the child in the long run are unknown. What is known is based on case-reports and small case-series solely. Both the coronaviruses causing Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) can cause a threat to pregnant women and their offspring, which leads to the question whether this could be the case also for SARS-CoV-2. Aims: To establish a biobank of biological material from infected as well as non-infected pregnant women and their offspring. To combine this biobank with Swedish quality and health care registers, computerized patient charts and questionnaire data, enabling both short-term follow up, such as obstetric outcomes, as well as long-term outcomes both for mother and child. To study how the pandemic situation affects both the mother and her partner in their experience of pregnancy, childbirth, and early parenthood. Design: A national Swedish multicentre study. Women are included when they have a positive test for SARS-CoV-2 or a clinical suspicion of coronavirus disease 2019 (COVID-19) (COVID-19 group). Pregnant women without COVID-19 symptoms will be included at their routine visits (Screening group). Blood samples and other biological material will be collected at different time-points. Additional predictors and outcomes are collected from the Swedish Pregnancy Register as well as obligatory Swedish health registers. The biobank and its linkage to health registers through the Swedish personal identification number will enable future research. Child development will be followed during the first year of life by questionnaires to the parents. Womens' and their partners' experience of childbirth and parenthood will be studied in form of questionnaires based on validated instruments as well as in form of interviews. Sweden is one of few countries with prerequisites enabling a nearly population-based follow-up, even under the pandemic condition with considerable strains for the health care system. Conclusion: This project will help obstetricians and neonatologists in better recognizing the clinical manifestations of the virus, identify possible risk factors during pregnancy and tailor therapies along with providing the right level of surveillance and management during pregnancy, delivery, and child health care. The project will also enable sharing important unusual outcome data with other research collaborators, e.g. outcome for pregnant women with diabetes.
Description: establish a biobank and database with bio-samples from both women that are not tested and presumed healthy as well as possibly ill and women confirmed tested positive for SARS-CoV-2 and their infants linked to Swedish health care registers including socio-economic factors and use serological and viral analyses from the biological samples to evaluate maternal, fetal and neonatal outcomes.Measure: Biobank with linkage to registers Time: 1-20 years
Description: study how women and their partners experience pregnancy, childbirth and early parenthood in the COVID-19-pandemic, both for women not tested and for women tested positive for SARS-CoV-2.Measure: Experiences of pregnancy during a pandemic Time: 1 year
The purpose of this study is to characterize the incidence and clinical features of the maternal COVID 19 infection, as well as the associated morbidity of the mother and the child, in the French context
Description: Maternal Criterion: Validated Composite Criterion of Severe Maternal Morbidity (Epimoms study ref 7). Neonatal Criterion: Mortality and Composite Criterion of Severe Neonatal Morbidity Perinatal asphyxia (arterial pH to cord-7.15 and/or an excess base - 10mmol/L and/or lactates-6 mmol/L, Apgar score at 5 minutes -7), neonatal encephalopathy, seizures, intraventricular hemorrhage, cerebral infarction, periventricular leucomalacia, ulcerative enterocolite, sepsis, respiratory distress syndrome, bronchopulmonary dysplasia, central catheter, ventilatory support, transfusionMeasure: Joint evaluation of morbi-mortality for mother and child up to 12 weeks postpartum Time: At12 weeks after delivery